1
David J Burke, Shaun E Buckley, Sherwood Russ Lehrman, Barbara Horsey O Connor, James Callaway, Christopher P Phillips: Immunoglobulin formulation and method of preparation thereof. Elan Pharmaceuticals, Crowell & Moring, January 8, 2013: US08349321 (32 worldwide citation)

A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which m ...


2
James Callaway: Pyrotechnic material. Secretary of State for Defence in her Britannic Majesty s Government of the United Kingdom of Great Britain, North Ireland of Defence Evaluation and Research Agency, Nixon & Vanderhye, January 11, 2000: US06013144 (7 worldwide citation)

An infrared emitting pyrotechnic material comprising a fibrous carbon containing substrate (1) onto one or both faces (4, 5) of which is vapor deposited a combustible material layer (2, 3) which may be protected by an additional coating (6, 7). The thickness and composition of each of the layers (2, ...


3
James Callaway: Infra-red emitting decoy flare. The Secretaryof State for Defence in Her Britannic Majesty s Government of the United Kingsom of Great Britain and Northern Ireland, Nixon & Vanderhye P C, April 14, 2009: US07516700 (7 worldwide citation)

An infra-red emitting decoy flare comprising a rupturable container 13 housing combustible flakes 1 and ignition means 20 for igniting the combustible flakes 1. Each of the combustible flakes 1 comprises a fibrous, carbon containing substrate on to which has been vapor deposited on one or both faces ...


4
John Wahren, Karin Ekberg, James Callaway: Methods and kits for preventing hypoglycemia. Cebix, Dennis A Bennett, Andrew Cubitt, December 21, 2010: US07855177 (3 worldwide citation)

Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associa ...


5
Ivan Lieberburg, James Callaway, Michael Grundman: Treatment of amyloidogenic diseases. Janssen Alzheimer Immunotherapy, Wyeth, Alston & Bird, December 24, 2013: US08613920 (2 worldwide citation)

The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient followi ...


6
James Callaway: Intravenous needle and holder assembly. Fleit Jacobson Cohn Price Holman & Stern, September 11, 1990: US04955872 (2 worldwide citation)

In an intravenous needle and needle holder assembly, the needle is attached to an inner case, through which intravenous fluid is supplied, by a length of flexible tubing. An outer case is provided which surrounds the tubing during insertion of the needle into a patient's vein, so as to rigidify the ...


7
Sheri Barrack, James Callaway, Michelle Mazzoni: Pegylated C-peptide. Cebix, Morrison & Foerster, April 8, 2014: US08691755 (1 worldwide citation)

The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activit ...


8
Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom: Immunotherapy regimes dependent on ApoE status. Wyeth, JANSSEN SCIENCES IRELAND UC, Alston & Bird, May 9, 2017: US09644025

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.


9
Sheri Barrack, James Callaway, Michelle Mazzoni: Pegylated C-peptide. Cebix, Morrison & Foerster, January 6, 2015: US08927488

The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activit ...


10
John Wahren, Sheri Barrack, James Callaway, Michelle Mazzoni, Howard Foyt, Mark Daniels: Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide. Cebix, Morrison & Foerster, February 24, 2015: US08962553

The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.